Randomized trial · people
Semaglutide: 16.0% weight loss at 68 weeks with therapy in STEP 3
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Paired with intensive counseling and an early low-calorie diet, semaglutide roughly tripled the weight loss seen with counseling alone, with gut side effects as the main tradeoff.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 611
- Published
- 2021
- Journal
- JAMA
What they tested
Does once-weekly semaglutide 2.4 mg add to the weight loss from intensive behavioral therapy and an early low-calorie diet in adults with overweight or obesity?
How the study was done
A randomized, double-blind, placebo-controlled phase 3a trial in 611 US adults without diabetes who had obesity, or overweight plus at least 1 related health problem. For 68 weeks, both groups got a low-calorie diet for the first 8 weeks and 30 counseling visits, plus either semaglutide or placebo (a dummy shot).

Model. Individual results vary.
What they found
At week 68, body weight changed by -16.0% on semaglutide and -5.7% on placebo, a difference of -10.3 percentage points. A 5% or greater weight loss was reached by 86.6% on semaglutide vs 47.6% on placebo. Losses of at least 10% were reached by 75.3% vs 27.0%, and losses of at least 15% by 55.8% vs 13.2%. Stomach and gut side effects were more common on semaglutide (82.8% vs 63.2%), and 3.4% on semaglutide stopped treatment because of them, vs 0% on placebo.
What it doesn’t show
The trial ran 68 weeks, so it doesn't show whether the weight loss lasts, which the authors say needs more study. Most participants were women (81.0%), and people with diabetes were not included.
The paper
Wadden et al. Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity: The STEP 3 Randomized Clinical Trial. JAMA. 2021.
The compound
More studies on Semaglutide
- Semaglutide: 11.85% more weight loss than placebo without diabetesMeta-analysis · people · 2022
- CagriSema: 18.4% weight loss vs 11.9% on semaglutide in REDEFINE 5Randomized trial · people · 2026
- CagriSema: HbA1c down 2.33% at 40 weeks in REIMAGINE 3Randomized trial · people · 2026
- Semaglutide (oral): smaller HbA1c drop than orforglipron in ACHIEVE-3Randomized trial · people · 2026
- Semaglutide (oral) did not slow early Alzheimer's in evoke trialsRandomized trial · people · 2026
- Cagrilintide-semaglutide: 20.4% weight loss at 68 weeks in REDEFINE 1Randomized trial · people · 2025
- Every study on Semaglutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.